Conference PaperPDF Available

Complete and stable objective response of 12 prostate cancer patients who were neither operated nor chemo-radiotreated but treated only with Di Bella Method (DBM) as first-line therapy.

Authors:
  • Fondazione Di Bella
  • Fondazione Giuseppe Di Bella ONLUS
  • Fondazione Giuseppe Di Bella - Onlus

Abstract

Complete and stable objective response of 12 prostate cancer patients who were neither operated nor chemo-radiotreated but treated only with Di Bella Method (DBM) as first-line therapy. OBJECTIVE: To evaluate the objective clinical, biochimical and metabolical response and the safety of the combined administration of Di Bella Method (DBM) in patients with a histological diagnosis of prostate adenocarcinoma. MATERIALS AND METHODS: Twelve patients with a certain diagnosis of prostate cancer and with measurable disease characteristics were evaluated according to the RECIST criteria. The 12 patients had not been previously operated on or chemo-radiotreated. After giving informed consent, they voluntarily accepted the administration of the treatment as first-line therapy. In detail, they were administered in the following ways: • All-trans retinoic acid solution (ATRA, 1543488.372 IU), axerophthol palmitate (909000 IU), beta-carotene (3334000 IU) in alpha tocopheryl acetate (1000000 IU), in a stoichiometric ratio of 1: 1: 4: 2; 2-3 in conjunction with • Dihydrotachisterol (cholecalciferol-Vit.D3, ATITEN ©; 15200 IU); • Somatostatin: scalar administration; • Tetracosactide (Synachten®-synthesis ACTH) with frequent monitoring of blood pressure and blood sugar; • Octreotide LAR (slow release) 30 mg intramuscular; • Enantone 3.75mg intramuscolar; • Bicatulamide (Casodex®) 50 mg; • Melatonin 5 mg; • Cabergoline 0.25 mg; • Bromocriptina® 2.5 mg; • Cyclophosphamide® (from 50 mg to 75mg) gradual dosage; • Ascorbic acid (Vit C) gradual dosage, with • Carbonate calcium 500 mg in the same glass; • Chondroitin sulfate 250 mg + Glucosamine 250 mg; • Sideral; • Calciolevofolinate 22 mg RESULTS AND CONCLUSIONS: This preliminary study shows that all 12 patients not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit and they alla achieved a five-year stable objective clinical instrumental, metabolic, biochemical complete remission with DBM applied as first-line therapy. Further clinical inestigations are recommended.
Complete and stable objective response of 12 prostate cancer patients who were neither
operated nor chemo-radiotreated but treated only with Di Bella Method (DBM) as first-line
therapy.
OBJECTIVE: To evaluate the objective clinical, biochimical and metabolical response and the
safety of the combined administration of Di Bella Method (DBM) in patients with a histological
diagnosis of prostate adenocarcinoma.
MATERIALS AND METHODS: Twelve patients with a certain diagnosis of prostate cancer and
with measurable disease characteristics were evaluated according to the RECIST criteria. The 12
patients had not been previously operated on or chemo-radiotreated. After giving informed consent,
they voluntarily accepted the administration of the treatment as first-line therapy.
In detail, they were administered in the following ways:
• All-trans retinoic acid solution (ATRA, 1543488.372 IU), axerophthol palmitate (909000 IU),
beta-carotene (3334000 IU) in alpha tocopheryl acetate (1000000 IU), in a stoichiometric ratio of
1: 1: 4: 2; 2-3 in conjunction with
• Dihydrotachisterol (cholecalciferol-Vit.D3, ATITEN ©; 15200 IU);
• Somatostatin: scalar administration;
• Tetracosactide (Synachten® - synthesis ACTH) with frequent monitoring of blood pressure and
blood sugar;
• Octreotide LAR (slow release) 30 mg intramuscular;
• Enantone 3.75mg intramuscolar;
• Bicatulamide (Casodex®) 50 mg;
• Melatonin 5 mg;
• Cabergoline 0.25 mg;
• Bromocriptina® 2.5 mg;
• Cyclophosphamide® (from 50 mg to 75mg) gradual dosage;
• Ascorbic acid (Vit C) gradual dosage, with
• Carbonate calcium 500 mg in the same glass;
• Chondroitin sulfate 250 mg + Glucosamine 250 mg;
• Sideral;
• Calciolevofolinate 22 mg
RESULTS AND CONCLUSIONS: This preliminary study shows that all 12 patients not previously
treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit and
they alla achieved a five-year stable objective clinical instrumental, metabolic, biochemical
complete remission with DBM applied as first-line therapy. Further clinical inestigations are
recommended.
ResearchGate has not been able to resolve any citations for this publication.
ResearchGate has not been able to resolve any references for this publication.